(VMD) Viemed Healthcare - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 370m USD | Total Return: 45.8% in 12m
Avg Turnover: 2.26M
EPS Trend: 95.7%
Qual. Beats: -1
Rev. Trend: 99.4%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Idiosyncratic Leader
Viemed Healthcare, Inc. (VMD) is a Lafayette-based provider of home medical equipment and post-acute respiratory services. The company specializes in disease management for Chronic Obstructive Pulmonary Disease (COPD) and neuromuscular conditions through the rental and sale of non-invasive and invasive ventilators, oxygen concentrators, and percussion vests. Its service portfolio extends to sleep apnea management, in-home testing, and healthcare staffing solutions.
The home medical equipment sector operates primarily on a recurring revenue model driven by long-term equipment rentals and the continuous supply of consumables. Demand in this industry is closely tied to aging demographics and a clinical shift toward lower-cost, home-based care settings to reduce hospital readmission rates.
Analyzing historical valuation trends on ValueRay can provide deeper context on the companys market positioning.
- Medicare reimbursement rate adjustments for non-invasive ventilation impact core revenue margins
- Expansion of respiratory care services into new geographic markets drives patient census growth
- Strategic acquisitions of regional home medical equipment providers accelerate inorganic market share
- Regulatory changes to competitive bidding programs affect long-term pricing for respiratory equipment
| Net Income: 14.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 16.77 > 1.0 |
| NWC/Revenue: 3.18% < 20% (prev 5.86%; Δ -2.68% < -1%) |
| CFO/TA 0.29 > 3% & CFO 57.1m > Net Income 14.9m |
| Net Debt (5.91m) to EBITDA (53.5m): 0.11 < 3 |
| Current Ratio: 1.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.5m) vs 12m ago -2.73% < -2% |
| Gross Margin: 57.32% > 18% (prev 0.59%; Δ 5.67k% > 0.5%) |
| Asset Turnover: 152.7% > 50% (prev 130.7%; Δ 21.93% > 0%) |
| Interest Coverage Ratio: 18.22 > 6 (EBITDA TTM 53.5m / Interest Expense TTM 1.31m) |
| A: 0.05 (Total Current Assets 49.8m - Total Current Liabilities 40.7m) / Total Assets 197.4m |
| B: 0.53 (Retained Earnings 105.5m / Total Assets 197.4m) |
| C: 0.13 (EBIT TTM 23.8m / Avg Total Assets 187.7m) |
| D: 2.45 (Book Value of Equity 126.3m / Total Liabilities 51.6m) |
| Altman-Z'' = 5.47 = AAA |
| DSRI: 0.95 (Receivables 31.2m/26.8m, Revenue 286.6m/232.8m) |
| GMI: 1.02 (GM 57.32% / 58.71%) |
| AQI: 1.37 (AQ_t 0.35 / AQ_t-1 0.25) |
| SGI: 1.23 (Revenue 286.6m / 232.8m) |
| TATA: -0.21 (NI 14.9m - CFO 57.1m) / TA 197.4m) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 9.62 with a total of 195,260 shares traded.
Over the past week, the price has changed by -0.21%,
over one month by -2.63%,
over three months by +11.86% and
over the past year by +45.76%.
Viemed Healthcare has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy VMD.
- StrongBuy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 11 | 14.3% |
P/E Trailing = 26.0811
P/E Forward = 22.0264
P/S = 1.291
P/B = 2.5715
Revenue TTM = 286.6m USD
EBIT TTM = 23.8m USD
EBITDA TTM = 53.5m USD
Long Term Debt = 8.33m USD (from longTermDebt, last quarter)
Short Term Debt = 2.07m USD (from shortTermDebt, last quarter)
Debt = 15.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.23m
Net Debt = 5.91m USD (calculated: Debt 15.7m - CCE 9.76m)
Enterprise Value = 375.9m USD (370.0m + Debt 15.7m - CCE 9.76m)
Interest Coverage Ratio = 18.22 (Ebit TTM 23.8m / Interest Expense TTM 1.31m)
EV/FCF = 14.50x (Enterprise Value 375.9m / FCF TTM 25.9m)
FCF Yield = 6.90% (FCF TTM 25.9m / Enterprise Value 375.9m)
FCF Margin = 9.04% (FCF TTM 25.9m / Revenue TTM 286.6m)
Net Margin = 5.20% (Net Income TTM 14.9m / Revenue TTM 286.6m)
Gross Margin = 57.32% ((Revenue TTM 286.6m - Cost of Revenue TTM 122.3m) / Revenue TTM)
Gross Margin QoQ = 56.27% (prev 57.89%)
Tobins Q-Ratio = 1.90 (Enterprise Value 375.9m / Total Assets 197.4m)
Interest Expense / Debt = 8.35% (Interest Expense 1.31m / Debt 15.7m)
Taxrate = 32.02% (1.28m / 3.99m)
NOPAT = 16.2m (EBIT 23.8m * (1 - 32.02%))
Current Ratio = 1.22 (Total Current Assets 49.8m / Total Current Liabilities 40.7m)
Debt / Equity = 0.11 (Debt 15.7m / totalStockholderEquity, last quarter 143.9m)
Debt / EBITDA = 0.11 (Net Debt 5.91m / EBITDA 53.5m)
Debt / FCF = 0.23 (Net Debt 5.91m / FCF TTM 25.9m)
Total Stockholder Equity = 139.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.93% (Net Income 14.9m / Total Assets 197.4m)
RoE = 10.66% (Net Income TTM 14.9m / Total Stockholder Equity 139.7m)
RoCE = 16.10% (EBIT 23.8m / Capital Employed (Equity 139.7m + L.T.Debt 8.33m))
RoIC = 10.88% (NOPAT 16.2m / Invested Capital 149.0m)
WACC = 7.23% (E(370.0m)/V(385.6m) * Re(7.30%) + D(15.7m)/V(385.6m) * Rd(8.35%) * (1-Tc(0.32)))
Discount Rate = 7.30% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -6.67 | Cagr: 0.12%
[DCF] Terminal Value 75.44% ; FCFF base≈25.9m ; Y1≈26.0m ; Y5≈27.6m
[DCF] Fair Price = 11.03 (EV 428.8m - Net Debt 5.91m = Equity 422.9m / Shares 38.3m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 95.71 | EPS CAGR: 24.26% | SUE: -1.49 | # QB: -1
Revenue Correlation: 99.42 | Revenue CAGR: 22.79% | SUE: 0.91 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.10 | Chg30d=-16.67% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.13 | Chg30d=+4.00% | Revisions=N/A | Analysts=1
EPS current Year (2026-12-31): EPS=0.46 | Chg30d=-5.21% | Revisions=-33% | GrowthEPS=+23.0% | GrowthRev=+17.4%
EPS next Year (2027-12-31): EPS=0.61 | Chg30d=-1.61% | Revisions=N/A | GrowthEPS=+34.1% | GrowthRev=+13.6%
[Analyst] Revisions Ratio: -33%